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GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
Cancer is the second leading cause of death globally. There were 14.1 million new cases worldwide 
and 8.2 million deaths in 2012.[1] The number of cancer deaths is rising due to an actual change in 
the prevalence of cancer, changes in worldwide population size, and changes in population age. 
Despite this absolute cancer increase, cancer death rates across many types have been falling. This 
is partly attributed to earlier detection and improved treatment.[2]
Several new treatment options have been introduced resulting in a more tailored cancer 
management.[3] When focusing on systemic treatment than tailoring this treatment to specific 
tumor characteristics, including DNA alterations, drugable mutations or characteristics indicating 
sensitivity for immune checkpoint inhibitors is possible in an increasing number of patients. 
However specific drug targets are still lacking in many cancer patients. Furthermore, most clinical 
trials have eligibility criteria resulting in a narrowly defined trial population. This jeopardizes the 
generalizability of trial results to daily practice[4], as factors such as comorbidities and suboptimal 
clinical condition are not included in registration trials.[5] Moreover rare niche populations such 
as men with breast cancer are still underserved. Clinical trials in these populations are difficult to 
perform and often require an international effort. 
Breast cancer is the most commonly diagnosed type of cancer in women worldwide. 
The nearly 1.7 million new cases diagnosed in 2012 represent about 12% of all new cancer 
cases and 25% of all cancers worldwide in women. [6] Initially, treatment of metastatic breast 
cancer consisted of chemotherapy or antihormonal therapy. Antihormonal therapy is currently 
administered in case of ≥1% positively staining tumor cells by immunohistochemistry of the 
estrogen or progesterone receptor which is the case in around 75% of the breast cancer patients.
[7, 8] Moreover approximately 15% of breast cancers show expression of the human epidermal 
growth factor receptor (HER)2 in general due to gene amplification of the HER2 gene.[9] The 
HER2 targeting antibody, trastuzumab, has been one of the first monoclonal antibodies broadly 
introduced into daily practice. As single agent, trastuzumab has limited antitumor activity in 
patients with HER2 overexpressing tumors, but combined with chemotherapy it showed clear 
antitumor activity even with improved overall survival in the curative and non-curative setting. By 
1996, clinical trials with trastuzumab had included over 900 women. Trastuzumab was fast-tracked 
by the Food and Drug Administration (FDA) and gained approval for the treatment of metastatic 
HER2 positive breast cancer in combination with chemotherapy in 1998 in the United States 
and gained approval by the European Medicines Agency (EMA) in 2000 for its use in Europe.[10] 
Trastuzumab thereafter became the cornerstone of treatment in these HER2 positive metastatic 
breast cancers.[11-13] In 2005 the addition of trastuzumab to chemotherapy as adjuvant treatment 
for most early breast cancers appeared also to reduce the recurrence rate and increased overall 
survival. It was therefore broadly implemented as standard of care.[14, 15] Now, trastuzumab is on 
the World Health Organization’s Essential Medicines List, representing the most effective and safe 
medicines needed for all eligible individuals in a health system.[16]  
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For the implementation of trastuzumab in standard daily care proper HER2 testing of the 
tumor tissue was critical. HER2 testing is performed by tumor immunohistochemistry and in-
situ hybridization. These techniques were initially found difficult to interpret and prone for 
misdiagnosis.[17, 18] An international effort to standardize these techniques has since then led to 
commonly adhered guidelines.[19] 
Eventually over several years of use of trastuzumab more data on safety, tolerability and efficacy 
in certain niche populations such as the elderly became available, allowing a more tailored approach 
in HER2 positive disease. [10-13] This insight is of particular importance as trastuzumab is currently 
still one of the most used agents in HER2 positive early and metastatic breast cancer. Evenmore 
overall survival in the metastatic setting has increased due to the progress which has been made 
in the development of new HER2 targeting agents.[20] Important new treatment options were the 
FDA and EMA approved anti-HER2 drugs pertuzumab and trastuzumab emtansine. Pertuzumab 
is a monoclonal antibody that binds the extracellular dimerization domain of HER2 and prevents 
it from binding to itself or to other members of the EGFR family. The addition of pertuzumab to 
trastuzumab and docetaxel improves in the metastatic setting overall survival from 40.8 months to 
56.5 months.[21] Trastuzumab emtansine, an antibody-drug conjugate composed of trastuzumab 
and a microtubule inhibitor, improved overall survival compared to lapatinib plus capecitabine in 
patients previously treated with trastuzumab and a taxane with less toxicity making it an efficacious 
and tolerable second line treatment.[22] Currently other approaches in HER2 positive breast cancers 
are explored such as other antibody drug conjugates targeting HER2, immune checkpoint inhibition 
and immuno-vaccines.(16-18) While these developments have been tremendously important for 
breast cancer outcome, it also serves as example for other (breast] cancer types, where also further 
improvement is warranted.
Aim of the thesis
The aim of this thesis is to study several aspects of treatment in patients with metastatic breast 
cancer. Special attention is paid to the implementation of treatment in daily oncology practice, 
treatment optimization in niche populations and the exploration of potential new drug targets.
Outline of the thesis
In chapter 2 we review literature with regards to immunotherapy in breast cancer subtypes 
including HER2 disease. The aim was to gain insight in the current evidence on predictive immune-
based biomarkers in breast cancer, immune-mediated effects from conventional therapies, as 
well as recent results and ongoing studies concerning immunotherapies in breast cancer. English 
language literature was reviewed by searching PubMed for relevant articles and by analyzing trials 
using ClinicalTrials.gov. during the period of September 2014 until June 2015. Abstracts of the 
American Society of Clinical Oncology annual meeting (2012 - 2015), San Antonio Breast Cancer 
symposium (2012 - 2014), American Association of Cancer Research annual meeting (2012 - 2015) 
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In chapter 3 we aimed to assess the concordance of the diagnostic HER2 assessment of tumor 
samples which were tested HER2 positive shortly after this test was introduced in daily practice. 
These HER2 assessments were made in the local pathology departments. We identified patients 
who were treated with trastuzumab for metastatic breast cancer in hospitals the Northern part of 
the Netherlands by studying the hospital pharmacy records in the period of 1999 to 2005. Tumor 
tissue was retrieved and a tissue micro-array was constructed. HER2 positivity of the tissue was 
centrally re-assessed using the tissue micro-array based upon the American Society of Clinical 
Oncology / College of American Pathologists clinical practice update in a certified pathology 
department.[23] Discordance in HER2 positivity, defined as tumor samples which were locally 
assessed as HER2 positive but were centrally assessed as negative, was analyzed. 
Following trastuzumab registration for the treatment of HER2 positive metastatic breast 
cancer, it was quickly implemented into daily practice.[14] Suddenly a new and potent treatment 
option became available for these patients. Trastuzumab was registered in the metastatic setting 
for first and subsequent therapy lines, either with chemotherapy or as single agent after treatment 
with at least two prior chemotherapy regimens.[24] As a result, trastuzumab use was broader in 
clinical practice than the first line combination with a taxane, as described in the pivotal trials 
on which registration was actually based.[10, 25] In chapter 4 we described how trastuzumab 
was used in daily practice in patients with metastatic breast cancer in the Northern part of the 
Netherlands between 2005 and 2009. The aim was to compare treatment outcome of trastuzumab 
treatment in daily practice with the results observed in the earlier published study. As elderly 
are underrepresented in clinical trials we specifically focused on this subgroup, by comparing its 
outcome with the non-elderly.[4, 26] The patient selection is described in chapter 3. Through the 
Netherlands Cancer Registry detailed information on patient, tumor and treatment characteristics 
was collected. Patient-, treatment- and outcome characteristics were compared for patients 
treated with trastuzumab in first line versus later therapy lines, and for patients aged below 65 
years versus 65 years or more. Also, outcome for patients treated in first line setting was compared 
to outcome of the two clinical trial populations. 
After implementation of trastuzumab in daily practice for metastatic breast cancer treatment, 
it was recognized that molecular characteristics such as HER2 expression are not necessarily 
breast cancer specific. This resulted in a number of initiatives to support pathway driven rather 
than tumor driven targeted therapy for niche populations. Trastuzumab was furthermore shown 
to be effective in combination with platinum based chemotherapy as first line treatment in HER2 
positive gastric cancer.[27] In chapter 4A we describe a case of a young female patient with 
HER2 positive metastatic disease, considered colorectal of origin. HER2 status was determined 
on a metastatic lesion as part of the search for the primary tumor. Next to conventional anatomic 
imaging molecular imaging was performed with a HER2 conjugated zirconium-89 positron 
emission tomography and HER2 directed therapy was initiated. 
A challenge in the implementation phase of a new treatment is how to extrapolate registered 
treatment data from a study population without comorbidities to a daily practice population. 
Patient with renal or hepatic impairment are often excluded from clinical trials. Hence knowledge 
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with regards to safety and tolerability is often lacking in these groups. It is therefore difficult 
to start treatment in these groups. This makes it essential to study pharmacokinetic and 
pharmacodynamics properties in this setting. Therapeutic drug monitoring can in strictly selected 
situations be helpful to guide treatment optimization.          Everolimus, an inhibitor of mammalian 
target of rapamycin directly interacts with mTORC1, inhibiting its downstream signaling. As 
a consequence, mRNAs that code for proteins implicated in the cell cycle and in the glycolysis 
process are impaired and tumor growth is inhibited. Everolimus is registered for advanced renal 
cell cancer, neuro-endocrine tumors and combined with the oral steroidal aromatase inhibitor, 
exemestane in metastatic breast cancer. In chapter 4B we described a patient on renal dialysis 
with an advanced grade 1 neuroendocrine tumor who was treated with a everolimus (5 mg once 
a day orally). As everolimus is in 98% metabolized by the liver in in only 2% in the urine, it was 
hypothesized to be safe despite of the dialysis setting.[28] After initiation of the treatment, whole 
blood everolimus concentrations at steady state were measured using liquid chromatography-
mass spectrometry to rule out toxic accumulation. 
Despite dramatic improvements in outcome for HER2 metastatic breast cancer due to HER2 
targeting, ultimately resistance will develop and patients will progress. Therefore, in chapter 5 we 
aimed to explore the relationship between the androgen receptor expression and the immune 
composition of the tumor microenvironment in HER2 positive breast cancer in light of its possible 
role in trastuzumab resistance.[29, 30] The androgen receptor is expressed in nearly 60% of the 
patients with HER2 positive breast cancer and androgens induce in apocrine breast cancer cell 
lines a proliferative response based on the interaction of the androgen receptor with the HER2 
pathway.[29, 31] The patient selection as described in chapter 3 resulted in a cohort consisting of 
tissue from patients with metastatic disease only. With use of the developed tissue micro-array 
of their primary tumors (chapter 3) we assessed androgen receptor expression and an immune 
profile tumor using immunohistochemistry. The immune profile measurements consisted of CD3, 
CD8, programmed cell death protein 1 (PD-1) and PD-1 ligand 1 (PD-L1), M2 tumor-associated 
macrophages and tumor-infiltrating lymphocytes. We moreover characterized a subgroup of 
patients from this cohort with tumors who might be immunogenic and immuno-evasive by 
creating a heatmap. 
Target identification in tumor tissue is particularly challenging in niche populations. These 
niche populations are often underrepresented in clinical trials compared to the general 
population. Specific patient, tumor and treatment characteristics are therefore often not well 
known and difficult to collect. It may well require an international effort to collect these data and 
recruit patients for well powered studies. In chapter 6 we aimed to correlate several markers 
in the tumors, such as the chemokine receptor CXCR2, to clinical outcome in males with breast 
cancer. This Dutch cohort consists of male patients diagnosed with and treated for breast cancer 
in daily practice and has a long term follow up. It is therefore a realistic reflection of this disease. 
Finally, a summary of the obtained results of this thesis is described in chapter 7 and these new 
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